



EUROPEAN COMMISSION
DG Competition

***Case M.10585 - APMH
INVEST / UNILABS***

Only the English text is available and authentic.

**REGULATION (EC) No 139/2004
MERGER PROCEDURE**

Article 6(1)(b) NON-OPPOSITION
Date: 20/01/2022

***In electronic form on the EUR-Lex website under document
number 32022M10585***



EUROPEAN COMMISSION

Brussels, 20.1.2022
C(2022) 430 final

PUBLIC VERSION

APMH Invest A/S
Esplanaden 50
1263 Copenhagen K
Denmark

**Subject: Case M.10585 – APMH INVEST / UNILABS
Commission decision pursuant to Article 6(1)(b) of Council Regulation
(EC) No 139/2004¹ and Article 57 of the Agreement on the European
Economic Area²**

Dear Sir or Madam,

1. On 17 December 2021, the European Commission received notification of a proposed concentration pursuant to Article 4 of the Merger Regulation by which APMH Invest A/S (“APMHI”, Denmark) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Unilabs Holding AB (“Unilabs”, Switzerland) by way of purchase of shares.³
2. The business activities of the undertakings concerned are:
 - for APMHI: globally active investment company controlled by A.P. Møller Holding A/S (Denmark), with investments in Maersk Tankers, Maersk Product Tankers, A.P. Møller Capital, KK Wind Solutions Holding A/S, Faersch, Nissens Cooling Solutions, Maersk Drilling, Danske Bank A/S and other financial investments in fixed income and securities. A.P. Møller Holding A/S also controls A.P. Møller-Mærsk A/S, an integrated transport and logistics company with worldwide activities,
 - for Unilabs, controlled by Cidra GP S.à.r.l (Luxembourg): provider of diagnostic services, which is active in the provision of bio-medical testing services (also known as CLTS), medical imaging services, reproductive medicine services and

¹ OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’). With effect from 1 December 2009, the Treaty on the Functioning of the European Union (‘TFEU’) has introduced certain changes, such as the replacement of ‘Community’ by ‘Union’ and ‘common market’ by ‘internal market’. The terminology of the TFEU will be used throughout this decision.

² OJ L 1, 3.1.1994, p. 3 (the ‘EEA Agreement’).

³ Publication in the Official Journal of the European Union No C 523, 28.12.2021, p. 8.

drug development services. Unilabs has laboratories and/or imaging centres in several EU- and non-EU countries.

3. After examination of the notification, the European Commission has concluded that the notified operation falls within the scope of the Merger Regulation and of paragraph 5(b) of the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004.⁴
4. For the reasons set out in the Notice on a simplified procedure, the European Commission has decided not to oppose the notified operation and to declare it compatible with the internal market and with the EEA Agreement. This decision is adopted in application of Article 6(1)(b) of the Merger Regulation and Article 57 of the EEA Agreement.

For the Commission

(Signed)
Olivier GUERSENT
Director-General

⁴ OJ C 366, 14.12.2013, p. 5.